
    
      The patient population will consist of 12 male HIV-positive patients who have been receiving
      stable antiretroviral therapy that includes raltegravir for a minimum of three months.
      Patients will be enrolled from one clinic in downtown Toronto and a hospital affiliated HIV
      specialty clinic in Ottawa, Ontario. Eligible patients will have evidence of full virologic
      suppression (HIV viral load < 50 copies/mL) at least one month prior to enrollment in the
      study. No changes will be made to the patients antiretroviral therapy during the course of
      the study.
    
  